Sulfonamide Derivatives in Antimicrobial Therapy: Structure-Activity Relationship and Medicinal Chemistry Perspectives

Sanjay R. Nishad¹*, Shejal S. Narwade², Pooja R. Naik³, Renuka B. Dhakne⁴, Vandana P. Patil⁵

¹ M. Pharm. (Pharmaceutics), University Department of Chemical Technology,

Chhatrapati Sambhajinagar, Maharashtra, India.

² B Pharm, Yash Institute of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, India.

³ M. Pharm (Quality Assurance), Dayanand College of Pharmacy, Maharashtra, India.

⁴Assistant Professor, Department of Pharmaceutics, University Department of Chemical Technology,

Chhatrapati Sambhajinagar, Maharashtra, India.

⁵Professor and HOD, Department of Pharmaceutics, Yash Institute of Pharmacy,

Chhatrapati Sambhajinagar Maharashtra, India.

*Corresponding Author E-mail: sanjaynishad7sn@gmail.com

ABSTRACT:

Sulfonamide derivatives continue to be a significant category of synthetic antimicrobial compounds with extensive therapeutic benefits. Their advancement started with the identification of Prontosil and its active metabolite sulfanilamide, paving the way for contemporary antibacterial chemotherapy. Sulfonamides resemble para-aminobenzoic acid in structure and hinder dihydropteroate synthase, preventing folate production. When combined with dihydrofolate reductase inhibitors like trimethoprim, they create a sequential blockade that improves antibacterial effectiveness. Studies on structure-activity demonstrate that the para-amino and sulfonyl groups on the benzene ring are crucial for activity, while alterations at the N1 and N4 positions significantly affect potency. Clinically, sulfonamides show efficacy against numerous gram-positive and certain gram-negative bacteria. Although resistance restricts their application against organisms such as Pseudomonas aeruginosa. Their importance goes beyond antibacterial treatment. Sulfonamide frameworks facilitate various biological uses, encompassing diuretics, antidiabetics, carbonic anhydrase inhibitors, anticonvulsants, anti-inflammatory medications, and new compounds aimed at enzymes like NaV1.7. They also act as important intermediates in synthetic chemistry via alkylation, arylation, and rearrangement processes. Although they are useful, sulfonamides pose significant precautions during pregnancy, infancy, and in individuals with known hypersensitivity. Sustained interest in their chemical adaptability and pharmacological range encourages ongoing investigation into novel sulfonamide-derived therapies

KEYWORDS: Sulfonamide, Antimicrobial therapy, Structure–Activity Relationship (SAR), Medicinal chemistry, Dihydropteroate synthase inhibition.

INTRODUCTION:

The discovery of drugs with sulfonamide derivatives can be likened more to a string of distinguished pearls. The main core is the same, but they differ in biological activities^1,2 The use of sulfonyl or sulfonamide groups in medicinal chemistry cannot be ignored, as it creates an important category of medications employed extensively as agriculture and medicinal compound^3–5 Sulfonamides, functioning as synthetic antifolic agents, have commonly been employed to treat bacterial infections in biological systems and have recently garnered significant interest in biology and medicine due to their extensive variety of biological applications, such as antibacterial effects antifungal, anti-inflammatory, antioxidant diuretics, anticancer, carbonic anhydrases, antitumor and GSK inhibitors for Alzheimer diseases, anti-tubercular, anti-diabetic, anti-HIV inhibitors, antiviral, anti-malaria, and others. Over150 FDA-approved drugs containing sulfur (S^VI) are accessible on the market, including celecoxib, meloxicam, piroxicam, sulfasalazine, and more.^3,6–11 Recently, specific sulfonamides have been noted for exhibiting intriguing antibacterial characteristics, which have been thoroughly investigated using the Quantitative Structure-Activity Relationship and Molecular Modeling (QSAR) approach^12,13

Table 1:  History and Development of Sulfonamide Antibacterial Agents^1,14,15

Year	Researcher/Discovery	Contribution	Application / Notes
1900s	Gerhard Domagk	Discovered antibacterial activity of Prontosil (sulfonamide dye).	Won Nobel Prize in 1939 for this discovery.
1936	Ernest Fourneau	Identified Prontosil as a prodrug converted to Sulfanilamide (active agent).	Explained mechanism in the human body.
1938	Montague Phillips	Discovery of Sulfapyridine.	Effective against pneumonia.
1941	—	Discovery of Sulfacetamide.	Used for urinary tract infections (UTIs).
1942	—	Discovery of Succinoylsulfathiazole.	Treatment of gastrointestinal (GI) infections.
1940s (WWII)	—	Sulfathiazole widely used.	Cured wound infections in soldiers.
Later	—	Limited use of Sulfanilamide.	Due to high toxicity in humans.
Later	—	Identification of newer compounds: Sulfisoxazole, Sulfamethoxazole, Sulfacetamide, Mafenide, Silver Sulfadiazine	Currently used sulfonamide antibacterial.

Overview of Sulfonamides:

Figure 1. General structure of sulfonamides if R1=R2=H is sulfanilamides

Sulfonamides are coeval with a vital class of compounds, exhibiting a full range of biological activities. Over the past two decades, research papers have been published citing a range of pharmacological activities arising from sulfonamide conjugates. Today, many leads bearing sulfonamide functionality are under clinical evaluation for the treatment of various medical conditions. Hence, without losing any emphasis on organic synthesis, a great deal of focus has been kept on developing a practical synthesis of sulfonamides. The scientific literature over time has been trying to prove the efficiency of the sulfonylation and n-alkylation approaches toward the synthesis of sulfonamides. The most common route involves a reaction between primary or secondary amines and sulfonyl chloride, usually with an organic or inorganic base^16,17

Figure 2.  An instance of azo reduction is prontosil, wherein intestinal bacteria transform inactive drugs into their pharmacologically effective state. Bacterial azoreductases found in the distal intestine break the N-N double bond and generate the active metabolite sulfanilamide ¹⁸

Structure-Activity Relationship:

Figure 3. Structure of sulfonamides

· The basic Sulphonamide ring is the minimum required structure for antibacterial activity.

· For activity, the Amino and Sulphonyl groups are required for activity and are located on the 1 and 4 positions of the ring.

· The N4 amino group can be changed into a prodrug, which later is converted back to free amino acids in vivo.

· The Sulphur atom must be attached directly to the benzene ring.

· Activity is reduced if the benzene ring is replaced with another ring or other substituents.

· Activity of N1 substituted amino sulphonamides varies with the nature of the substituent at the amino group. An electron rich character towards the -SO2 group increases the bacteriostatic activity. ¹⁹

Mechanism of Action (MOA)

The sulfonamides are structural representatives of para-aminobenzoic acid (PABA) leading to competition suppression of dihydropteroate synthase (DHPS), an enzyme that transforms PABA into dihydrofolic acid (folic acid). An additional enzyme, dihydrofolate reductase, operates in a sequential manner. transforms dihydrofolate into tetrahydrofolate (folinic acid). Diaminopyrimidines like trimethoprim block dihydrofolate reductase, which is deeper within the folic acid synthesis route. The pairing of a sulfonamide and a diaminopyrimidine, such as trimethoprim or methoprim, Methoprim, known as pyrimethamine, is also called a "enhanced" sulfonamide

The inclusion of any of these dihydrofolate reductase inhibitors to a sulfonamide offer successive obstruction of the enzymes leading to the final synergistic suppression of the creation of purine bases that serve as the foundation. segments of nucleic acids thereby disrupting protein synthesis and capacity of a cell to reproduce. Observe the sequential inhibition of the enzymes. Dihydropteroate synthase and Dihydrofolate reductase upon the addition of a diaminopyrimidine^20–22

Figure 4. Mechanism of Action of sulphonamide

Classification Of Sulphonamides

Table 2.  Chemical / structural classification ^23–26

Class (basis)	Subtype / description	Representative examples (from your text)
Aryl derivatives	Sulfonamides where the sulfonyl (SO₂) group is attached to an aryl (benzene) system	Sulfamethoxazole, Sulphanilamide
Heterocyclic six-membered rings	Heterocycles fused/attached to the sulfonamide with 6-membered ring systems	Pyridine, Pyrimidine, Pyridazine, Pyrazine derivatives
Heterocyclic five-membered rings	Heterocycles with 5-membered rings attached to the sulfonamide	Thiazole, Oxazole, Isoxazole, 1,3,4-Thiadiazole, Pyrazole

Table 3. Pharmacokinetic / clinical classification (by half-life)²⁷

Group	Half-life (hours)	Example drugs	Clinical uses
Short-acting	< 10 h	Sulfamethizole, Sulfisoxazole, Sulfanilamide	Urinary tract infections
Intermediate-acting	10–24 h	Sulfamethoxazole, Sulfacetamide, Sulfadiazine	Various infections noted activity
Long-acting	> 24 h	Sulfadimethoxine, Sulfadoxine	Used historically for longer-duration therapy

Antibacterial Sulfonamides:

Sulphonamides are a vital group of antibiotic agents covering a broad spectrum of activity; they are highly effective against the gram positive and some gram negative bacteria. Some of the gram-negative organisms susceptible to sulfonamides include species of Klebsiella, Salmonella, E. coli, and Enterobacter; however, sulfonamides do not demonstrate inhibitory action (bacterial resistance) against Pseudomonas aeruginosa and Serratia species.^28,29 Sulfa drugs that include the sulfonamide functional group, exhibiting a wide range of biological activities, transformed the domain of medical sciences^30,31

Importance in Medicinal Chemistry:

Table 4. Sulfa drugs producing various pharmacological        activities ³²

Drug Name	Use
Sulfacetamide	Topical antibiotic
Sulfadiazine	Treats urinary tract infections and burns
Sulfalene	Treats chronic bronchitis, urinary tract infections and malaria
Sultiam	Used as an anticonvulsant
Glipizide	Treats type 2 diabetes mellitus
Tolbutamide	Treats type 2 diabetes mellitus
Tinidazole	Anti-protozoal drug
Hydrochlorothiazide	Diuretic medication
Satavaptan	Vasopressin-2 receptor antagonist
Bosentan	Treats pulmonary artery hypertension
Celecoxib	Nonsteroidal anti-inflammatory drug

Table 5. Chemical synthesis of sulfonamides and Biological applications of sulfonamide³³

Synthetic applications of sulfonamide	1 Sulfonamide moiety as an activating group	Used to activate adjacent functional groups, stabilize intermediates, and direct reactions such as electrophilic aromatic substitution or metal‐catalyzed transformations.
	2 Alkylations / Arylations of sulfonamide	Sulfonamides undergo N-alkylation and N-arylation using bases or metal catalysts, enabling construction of N-substituted sulfonamides important in medicinal chemistry.
	3 Rearrangement of sulfonamide compounds	Includes Smiles rearrangement, Lossen-type rearrangements and other nitrogen–sulfur migrations that create new C–N or N–heterocyclic frameworks.
	4 Other synthetic applications	Serve as protecting groups for amines, precursors in heterocycle synthesis, auxiliaries in asymmetric reactions, and intermediates in coupling reactions.
Biological applications of sulfonamide	1 Sulfonamide as therapeutic agents	Widely used as antimicrobials, diuretics, antidiabetics, antithyroid agents and anticonvulsants.
	2 Anti-carbonic anhydrase activity	Act as zinc-binding inhibitors of carbonic anhydrase isoforms, useful in glaucoma therapy, diuretics and anticancer research.
	3 NaV1.7 inhibitors	Certain sulfonamide sc affolds inhibit voltage-gated sodium channel NaV1.7, explored for non-opioid analgesics.
	4 Other biological applications	Show antiviral, anticancer, anti-inflammatory, antifungal and enzyme-modulating properties across various biological systems.

Contraindications to Sulfonamides:

Sulfonamides are not advised for patients with a history of allergic reactions to them or those with porphyria. Sulfonamides are ineffective in eliminating group A streptococci in individuals with pharyngitis and should not be employed for treating group A streptococcal pharyngitis^34,35,36

Use of Sulfonamides During Pregnancy and Breastfeeding:

The evidence linking sulfonamides to birth defects is inconsistent. Research on animals involving sulfonamides indicates some risk, and sufficient studies have not been conducted on pregnant women.

Use in the near term and in nursing mothers is not recommended, along with its use in patients under 2 months old (unless as an adjunctive treatment with pyrimethamine for congenital toxoplasmosis). When utilized in the short-term during pregnancy or in newborns, these drugs elevate blood concentrations of unconjugated bilirubin and heighten the risk of kernicterus in the fetus or infant. ³⁷

Bacterial Resistance to Sulphonamides:

Antimicrobial resistance poses an increasing risk to the health of humans, animals, and the environment, primarily fueled by excessive antibiotic use and insufficient new drug research. Bacteria gain resistance via vertical evolution, in which genetic mutations are inherited by their offspring, or through horizontal evolution, where resistance genes transfer among various bacteria.

Resistance to sulfonamides has been extensively documented, including resistance to trimethoprim–sulfamethoxazole and sulfadiazine. Resistant genes have been found in environmental sources like soil adjacent to poultry farms, and resistance has propagated among pathogenic bacteria. These issues emphasize the critical necessity to create new and more efficient antimicrobial agents.^28,38–40

CONCLUSION:

The class of sulfonamide derivatives continues to serve as a vital group of synthetic antimicrobial agents used in medicinal chemistry research. The discovery of Prontosil together with its active metabolite Sulfanilamide established these compounds as essential components for developing antibacterial chemotherapy. The dihydropteroate synthase enzyme becomes inhibited by their chemical structure which mirrors the structure of para-aminobenzoic acid. Their combination with Trimethoprim leads to a dual blockage that disrupts folate synthesis.

The structure-activity relationship (SAR) research shows that the para-amino and sulfonyl groups plus N1 and N4 position substitutions serve as the crucial factors that determine a compound's strength and how it moves through the body. The sulfonamide scaffold shows its usefulness beyond antibacterial applications because it functions as the basis for diuretic drugs and anti-diabetic medications and anti-inflammatory drugs and enzyme inhibition treatments.

Ongoing research investigates new chemical compounds which show potential to enhance effectiveness while decreasing harmful effects.

REFERENCE:

1. Yousef F, Mansour O, Journal JHI vitro I vivo I silico, 2018  undefined. Sulfonamides: historical discovery development (structure-activity relationship notes). oap-lifescience.org F Yousef, O Mansour, J HerbaliIn-vitro In-vivo In-silico Journal, 2018 oap-lifescience.org. https://www.oap-lifescience.org/iiij/article/749

2. MD MS. Sulfa allergy: cross-reactivity versus multiple concurrent allergies. 2013; https://scholarlycommons.libraryinfo.bhs.org/all_works/7830/

3. Kumar Verma S, Verma R, Xue F, Kumar Thakur P, Girish YR, Rakesh KP. Antibacterial activities of sulfonyl or sulfonamide containing heterocyclic derivatives and its structure-activity relationships (SAR) studies: A critical review. Bioorganic Chemistry. 2020 Dec 1; 105: 104400. doi :10.1016/J.BIOORG.2020.104400

4. Majumdar KC, Mondal S. Recent developments in the synthesis of fused sultams. Chemical Reviews. 2011 Dec 14; 111(12): 7749–73. https://pubmed.ncbi.nlm.nih.gov/21894896/, doi :10.1021/CR1003776

5. Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? Journal of Medicinal Chemistry. 1999 Jul 15; 42(14): 2641–50. https://pubmed.ncbi.nlm.nih.gov/10411484/, doi :10.1021/JM9900523

6. Kalgutkar AS, Jones R, Sawant A. Sulfonamide as an Essential Functional Group in Drug Design. 2010; https://books.rsc.org/books/edited-volume/1291/chapter/939871/Sulfonamide-as-an-Essential-Functional-Group-in, doi :10.1039/BK9781849730167-00210

7. Huang YM, Alharbi NS, Sun B, Shantharam CS, Rakesh KP, Qin HL. Synthetic routes and structure-activity relationships (SAR) of anti-HIV agents: A key review. European journal of medicinal chemistry. 2019 Nov 1;181. https://pubmed.ncbi.nlm.nih.gov/31401538/, doi :10.1016/J.EJMECH.2019.111566

8. Gawin R, De Clercq E, Naesens L, Koszytkowska-Stawińska M. Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure. Bioorganic & Medicinal Chemistry. 2008 Sep 15; 16(18): 8379–89. https://pubmed.ncbi.nlm.nih.gov/18778942/, doi : 10.1016/J.BMC.2008.08.041

9. Lal J, Gupta SK, Thavaselvam D, Agarwal DD. Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides. European Journal of Medicinal Chemistry. 2013; 64: 579–88. https://pubmed.ncbi.nlm.nih.gov/23685942/, doi :10.1016/J.EJMECH.2013.03.012

10. Liu H, Long S, Rakesh KP, Zha GF. Structure-activity relationships (SAR) of triazine derivatives: Promising antimicrobial agents. European Journal of Medicinal Chemistry. 2020 Jan 1;185. https://pubmed.ncbi.nlm.nih.gov/31675510/, doi :10.1016/J.EJMECH.2019.111804

11. Konda S, Raparthi S, Bhaskar K, Munaganti RK, Guguloth V, Nagarapu L, et al. Synthesis and antimicrobial activity of novel benzoxazine sulfonamide derivatives. Bioorganic & Medicinal Chemistry Letters. 2015 Apr 1; 25(7): 1643–6. https://pubmed.ncbi.nlm.nih.gov/25754493/, doi :10.1016/J.BMCL.2015.01.026

12. Genç Y, Özkanca R, Bekdemir Y. Antimicrobial activity of some sulfonamide derivatives on clinical isolates of Staphylococus aureus. Annals of Clinical Microbiology and Antimicrobials. 2008 Aug 20;7(1):1–6. https://link.springer.com/articles/10.1186/1476-0711-7-17, doi :10.1186/1476-0711-7-17/TABLES/3

13. Zani F, Vicini P. Antimicrobial activity of some 1,2-benzisothiazoles having a benzenesulfonamide  moiety. Archiv der Pharmazie. 1998 Jun;331(6):219–23. , doi :10.1002/(sici)1521-4184(199806)331:6<219::aid-ardp219>3.0.co;2-u

14. Pareek A, Rani P, Kishore AD. A SHORT REVIEW ON: SULPHONAMIDES. International Journal of Pharma and Bio Sciences. 2013; 4(4). http://ijpbs.net/details.php?article=2770

15. Pasteur L. Book and Media Reviews T He F Irst M Iracle D Rugs : H Ow the S Ulfa D Rugs. 2014; 12–3. https://global.oup.com/academic/product/the-first-miracle-drugs-9780195187755

16. El-Gaby MSA, Ammar YA, El-Qaliei MIH, Ali AM, Hussein MF, Faraghally FA. Sulfonamides: Synthesis and the recent applications in medicinal chemistry. Egyptian Journal of Chemistry. 2020 Dec 1; 63(12): 5289–327. , doi :10.21608/EJCHEM.2020.33860.2707

17. Tonmoy Chitta Das, Syed Aziz Quadri1, Mazahar Farooqui. Recent advances in synthesis of sulfonamides: A review. Chemistry & Biology Interface. 2018;8(4):194–204.

18. _Dr. S. Mondal. Sulphonamides and Sulfones  [Internet]. https%3A%2F%2Fwww.researchgate.net%2Fprofile%2FDr-Sumanta-Mondal%2Fpublication%2F351663612_BP601T_MEDICINAL_CHEMISTRY_-III%2Flinks%2F60a419c0299bf1921e34777b%2FBP601T-MEDICINAL-CHEMISTRY-III.pdf

19. Kawade DP, Lokhande AS, M.Raut S, Ikhankar MA, Kawade DP, Lokhande AS, et al. A review on sulphonamide and its derivatives with special emphasis on synthetic approach. JETIR. 2022; 9(1): c621–9. https://www.jetir.org/view?paper=JETIR2201279

20. Seydel JK. Sulfonamides, Structure-Activity Relationship, and Mode of Action: Structural Problems of the Antibacterial Action of 4-Aminobenzoic Acid (PABA) Antagonists. Journal of Pharmaceutical Sciences. 1968 Sep 1; 57(9): 1455–78. , doi :10.1002/JPS.2600570902

21. Chhablani A, Jain V, Makasana J. Sulfonamides: Historical Perspectives, Therapeutic Insights, Applications, Challenges, and Synthetic Strategies. ChemistrySelect. 2025 Aug 1;10(29):e02122. https://onlinelibrary.wiley.com/doi/full/10.1002/slct.202502122, doi :10.1002/SLCT.202502122

22. Hassanein MM. Sulfonamides: far from obsolete. International Journal of Contemporary Pediatrics. 2019 Oct 21;6(6):2740. , doi :10.18203/2349-3291.IJCP20194768

23. El-Gaby MSA, Ammar YA, El-Qaliei MIH, Ali AM, Hussein MF, Faraghally FA. Sulfonamides: Synthesis and the recent applications in Medicinal Chemistry. Egyptian Journal of Chemistry. 2020 Dec 1; 63(12): 5289–327. https://ejchem.journals.ekb.eg/article_107311.html, doi :10.21608/EJCHEM.2020.33860.2707

24. Locuson CW, Gannett PM, Ayscue R, Tracy TS. Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9. Journal of Medicinal Chemistry. 2007 Mar 22; 50(6): 1158–65. https://pubmed.ncbi.nlm.nih.gov/17311370/, doi :10.1021/JM060706P

25. Laurence Brunton, John Lazo, Keith Parker. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, Eleventh Edition - Laurence Brunton, John Lazo, Keith Parker - Google Books [Internet]. https://books.google.co.in/books/about Goodman_Gilman_s_The_Pharmacological_Bas.html?id=PtWdBgnQdjMC&redir_esc=y

26. Nachilobe P. Determination of trimethoprim and sulphadoxine residues in porcine tissues and plasma. Canadian Journal of Veterinary Research = Revue canadienne de recherche vétérinaire. 2016 Apr 4; https://www.academia.edu/24008652/Determination_of_trimethoprim_and_sulphadoxine_residues_in_porcine_tissues_and_plasma

27. Sulphonamide or Sulpha-Drugs. In: Concise Organic Pharmaceutical Chemistry -2.

28. Ovung A, Bhattacharyya J. Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions. Biophysical Reviews. 2021 Apr 1; 13(2): 259. https://pmc.ncbi.nlm.nih.gov/articles/PMC8046889/, doi :10.1007/S12551-021-00795-9

29. JWhite R, Cooper R. Silver sulphadiazine: a review of the evidence. Clinical Review. https://www.researchgate.net/profile/Richard-White-7/publication/242562122_Silver_sulphadiazine_A_review_of_the_evidence/links/54b2a1b10cf2318f0f9537fb/Silver-sulphadiazine-A-review-of-the-evidence.pdf

30. Mohsein HF, Majeed NS, Al-Ameerhelal TA. Synthesis and Characterization of some new Heterocyclic compounds containing a Sulfonamide Moiety. Research Journal of Pharmacy and Technology. 2019 Jul 25; 12(7): 3282–8. https://rjptonline.org/AbstractView.aspx?PID=2019-12-7-28, doi :10.5958/0974-360X.2019.00555.9

31. Eicher T, Hauptmann S, Speicher A. The Chemistry of Heterocycles. The Chemistry of Heterocycles. 2003 Jun 25; https://onlinelibrary.wiley.com/doi/book/10.1002/352760183X, doi :10.1002/352760183X

32. Hebat-Allah S. Abbas, Somaia S. Abd El-Karim, Nayera A.M. Abdelwahed. Synthesis and biological evaluation of sulfonamide derivatives as antimicrobial agents. Acta Poloniae Pharmaceutica ñ Drug Research. 2017; 74: 849–60.

33. Mondal S, Malakar S. Synthesis of sulfonamide and their synthetic and therapeutic applications: Recent advances. Tetrahedron. 2020 Nov 27; 76(48): 131662. , doi :10.1016/J.TET.2020.131662

34. Sulfa Allergy: Symptoms & Drugs To Avoid [Internet]. https://my.clevelandclinic.org/health/diseases/25131-sulfa-allergy

35. Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of ‘sulfa’ allergy. Drug Safety. 2001 Nov 21; 24(4): 239–47. https://link.springer.com/article/10.2165/00002018-200124040-00001, doi :10.2165/00002018-200124040-00001/METRICS

36. Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, et al. Absence of Cross-Reactivity between Sulfonamide Antibiotics and Sulfonamide Nonantibiotics. New England Journal of Medicine. 2003 Oct 23; 349(17): 1628–35. https://www.nejm.org/doi/full/10.1056/NEJMoa022963, doi :10.1056/NEJMOA022963/SUPPL_FILE/NEJM_STROM_1628SA1-2.PDF

37. Sulfonamides - Infectious Diseases - MSD Manual Professional Edition [Internet]. https://www.msdmanuals.com/professional/infectious-diseases/bacteria-and-antibacterial-medications/sulfonamides#Indications_v1004563

38. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathogens and Global Health. 2015 Oct 1; 109(7): 309–18. , doi :10.1179/2047773215Y.0000000030

39. Laws M, Shaaban A, Rahman KM. Antibiotic resistance breakers: current approaches and future directions. FEMS microbiology reviews. 2019 Jun 10; 43(5): 490–516. https://pubmed.ncbi.nlm.nih.gov/31150547/, doi :10.1093/FEMSRE/FUZ014

40. Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2001 Jun 1; 32(11): 1608–14. https://pubmed.ncbi.nlm.nih.gov/11340533/, doi :10.1086/320532

Received on 31.01.2026      Revised on 03.04.2026

Accepted on 13.05.2026      Published on 04.07.2026

Available online from July 30, 2026

Asian J. Research Chem.2026; 19(4):317-322.

DOI: 10.52711/0974-4150.2026.00049

©A and V Publications All Right Reserved

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.